A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran-Reference-Cited by-同舟云学术

A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran

Published:2023-07-01 Issue:2 Volume:22 Page:1263-1271
ISSN:2251-6581
Container-title:Journal of Diabetes & Metabolic Disorders
language:en
Short-container-title:J Diabetes Metab Disord

Author:

Fariman Soroush Ahmadi,Nosrati Marzieh,Rahmani Parham,Nikfar Shekoufeh

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40200-023-01243-z.pdf

Reference33 articles.

1. Bhutani J, Bhutani S. Worldwide burden of diabetes. Indian J Endocrinol Metab. 2014;18(6):868–70.

2. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021;183.

3. Zhang P, Gregg E. Global economic burden of diabetes and its implications. lancet Diabetes & Endocrinol. 2017;5(6):404–5. Available from: http://europepmc.org/abstract/MED/28456417

4. Esteghamati A, Etemad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Noshad S, et al. Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005–2011. Diabetes Res Clin Pract. 2014;103(2):319–27.

5. Javanbakht M, Mashayekhi A, Baradaran HR, Haghdoost A, Afshin A. Projection of diabetes population size and associated economic burden through 2030 in Iran: evidence from micro-simulation Markov model and bayesian meta-analysis. PLoS ONE. 2015;10(7):e0132505.